Cargando…
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Cancer is one of the leading causes of death worldwide due to high heterogeneity. Although chemotherapy remains the mainstay of cancer therapy, non-selective toxicity and drug resistance of mono-chemotherapy incur broad criticisms. Subsequently, various combination strategies have been developed to...
Autores principales: | Wu, Mo, Huang, Wei, Yang, Nan, Liu, Yanyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644565/ https://www.ncbi.nlm.nih.gov/pubmed/36348391 http://dx.doi.org/10.1186/s40164-022-00347-1 |
Ejemplares similares
-
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020) -
Antibody-drug conjugates: Present and future
por: Beck, Alain, et al.
Publicado: (2013) -
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014) -
Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021) -
Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
por: Mehrling, Thomas, et al.
Publicado: (2018)